Memory shares plunge as lead drug fails trial

Shares of Memory Pharmaceuticals plunged this morning after researchers announced that its lead drug failed to achieve any of its endpoints in a mid-stage study for mania in bipolar patients. The volunteers in the MEM 1003 trial were studied to see if they achieved a 50 percent improvement on a standard mania scale. No serious side effects were recorded, but that was cold comfort to investors. Memory shares quickly lost about a third of their value in early trading. MEM 1003 is also being studied as a therapy for Alzheimer's. Memory was a 2003 Fierce 15 winner.

- check out Memory's press release
- read the AP report on Memory Pharmaceuticals

Suggested Articles

J&J's EGFR-fighting combo stopped tumor growth in 60% of patients whose lung cancer got worse after taking AstraZeneca's Tagrisso.

Amgen's KRAS inhibitor curbed tumor growth in 88% of patients with non-small cell lung cancer, shrinking tumors in one-third of them.

The trial squeezed under the bar for statistical significance by improving on the median progression-free survival of Zytiga by two months.